Shares of Agenus Inc. (NASDAQ:AGEN) fell 3.6% during mid-day trading on Wednesday . The stock traded as low as $6.17 and last traded at $6.19, with a volume of 511,766 shares trading hands. The stock had previously closed at $6.42.

A number of brokerages have recently weighed in on AGEN. Zacks Investment Research upgraded Agenus from a “sell” rating to a “hold” rating in a research report on Tuesday, July 5th. Maxim Group reiterated a “buy” rating and set a $7.00 price target on shares of Agenus in a research report on Thursday, July 28th. Jefferies Group reiterated a “buy” rating on shares of Agenus in a research report on Tuesday, August 23rd. Finally, HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Agenus in a research report on Sunday, July 31st. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Agenus currently has a consensus rating of “Buy” and a consensus target price of $10.25.

The firm’s market capitalization is $538.85 million. The stock has a 50-day moving average price of $5.64 and a 200 day moving average price of $4.34.

Agenus (NASDAQ:AGEN) last announced its earnings results on Thursday, July 28th. The company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.34) by $0.01. The company earned $6.59 million during the quarter, compared to analysts’ expectations of $5.12 million. On average, equities research analysts anticipate that Agenus Inc. will post ($1.27) earnings per share for the current fiscal year.

Agenus Inc (Agenus) is an immuno-oncology company. The Company is engaged in discovering and developing treatments for patients with cancer. Its approaches are driven by platforms and programs, which include antibody discovery platform, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage and AutoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.